Information Provided By: 
Fly News Breaks for February 28, 2019
IONS
Feb 28, 2019 | 08:02 EDT
BMO Capital analyst Do Kim raised his price target on Ionis Pharmaceuticals to $82 and kept his Outperform rating after its better than expected Q4 results. The analyst is also raising his FY19 and FY20 EPS targets by 28c and 13c to $1.59 and $2.19 respectively on expectations of lower R&D expense projections, adding that more "upside could come from Tegsedi quarterly beats, potential Waylivra refiling, and visibility into an accelerated path for Huntington's".
News For IONS From the Last 2 Days
There are no results for your query IONS
